Nuclera

Nuclera is a US and UK-based biotechnology company that aims to make proteins accessible for life science researchers. The company has developed the eProtein Discovery platform, a benchtop system that enables scientists to obtain active proteins from DNA in just 48 hours. This technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing for rapid progress on protein projects through an automated, high-throughput protein access system.

Nuclera's system automates construct screening to inform off-platform protein scale-up, delivering reliable protein samples (μg-mg amounts) in less than 48 hours. The eProtein Discovery platform addresses the time and cost challenges associated with manufacturing custom protein reagents required in drug discovery. By accelerating drug discovery processes by up to 30 times, the platform provides sequences and optimal conditions to inform protein manufacturing.

In May 2021, Nuclera renovated its US facility, focusing on R&D innovation to secure its position as a technological innovator in the protein prototyping space. The facility includes over 1,000 square feet dedicated to cartridge manufacturing to support the company's growth.

Nuclera's technology significantly reduces the turnaround time of target discovery, identifying the most promising proteins within days. It offers multiple DNA construct screening and protein synthesis reagents for solubility assessment, ensuring researchers move forward with the ideal, soluble protein. Additionally, the system provides insights into specific traits and functionality of proteins, increasing the chances of identifying the most suitable candidate for the intended purpose while minimizing investment and decision-making time.

In June 2024, Nuclera secured two Innovate UK grants totaling GBP 1.14 million to further develop the eProtein Discovery system.

Key customers and partnerships

Nuclera's eProtein Discovery platform has been adopted by various customers, including pharmaceutical companies within the top 10, leading biotech firms, and prominent contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). The company has successfully deployed its systems to protein science groups within these organizations.

Nuclera has also formed partnerships with DeepMirror, Imperial College London's Dr. Konstantinos Beis, and Diamond Light Source's Dr. Andrew Quigley as part of the Innovate UK grants to further develop and evaluate the eProtein Discovery platform.